Werewolf Therapeutics Q1 EPS $(0.39) Misses $(0.35) Estimate, Sales $742.00 Miss $1.82M Estimate
Werewolf Therapeutics Q1 EPS $(0.39) Misses $(0.35) Estimate, Sales $742.00 Miss $1.82M Estimate
Werewolf Therapeutics第一季度每股收益美元（0.39美元）未達到預期（0.35美元），銷售額爲742.00美元，低於182萬美元的預期
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.35) by 11.43 percent. This is a 14.71 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $742.00 which missed the analyst consensus estimate of $1.82 million by 99.96 percent. This is a 99.98 percent decrease over sales of $4.46 million the same period last year.
Werewolf Therapeutics（納斯達克股票代碼：HOWL）公佈的季度虧損爲每股0.39美元，比分析師普遍預期的0.35美元（0.35美元）低11.43％。這比去年同期每股虧損0.34美元（0.34）下降了14.71％。該公司公佈的季度銷售額爲742.00美元，比分析師普遍預期的182萬美元低99.96％。這比去年同期的446萬美元銷售額下降了99.98％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。